| Literature DB >> 35832514 |
Wenfeng Xu1,2, Shuo Xu1,2, Yongmei Kuang1,2, Xiaorong He1,2, Pengfei Jin1,2.
Abstract
Niuhuang Jiedu Tablets (NJT) is a popular over-the-counter traditional Chinese medicine (TCM) preparation. It is composed of realgar (As2S2) and seven other TCMs. The safety of NJT is of growing concern because arsenic (As) is carcinogenic to humans. The toxicity of realgar in vivo can mainly be attributed to the absorbed and accumulated As. This study investigated the correlation between the detoxification effects of the other TCMs in NJT on realgar and their influences on arsenic accumulation of realgar in mice. Histopathological examination, clinical biochemical test, and metabolic profiling analysis were used to evaluate the toxicity of realgar. The concentration of arsenic in mice whole blood as the hazard indicator was determined by inductively coupled plasma mass spectrometry (ICP-MS). The compatibility of NJT could decrease arsenic bioaccumulation of realgar in mice whole blood and consequently reduce the toxicity of realgar, which could be considered as one detoxification mechanism to realgar in NJT. The combination of Rhei Radix et Rhizoma, Scutellariae Radix, Platycodonis Radix, and Glycyrrhizae Radix et Rhizoma exhibited almost the same effects as NJT in regulating the serum biochemical parameters and metabolic profiles disturbed by realgar and in reducing arsenic accumulation of realgar in mice whole blood.Entities:
Year: 2022 PMID: 35832514 PMCID: PMC9273386 DOI: 10.1155/2022/7406694
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Grouping scheme of this experiment.
| Group name | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | R | NJT | RBC | RBS | RGF | RRR | RSR | RPR | RGR | RFH | |
| Realgar (R, 0.3 g/kg) | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
|
| √ | √ | |||||||||
|
| √ | √ | |||||||||
|
| √ | √ | |||||||||
|
| √ | √ | √ | ||||||||
|
| √ | √ | √ | ||||||||
|
| √ | √ | √ | ||||||||
|
| √ | √ | √ | ||||||||
Key: √, corresponding TCM included.
ICP-MS operating parameters.
| Parameter | Value |
|---|---|
| RF power | 1550 W |
| RF matching | 1.2 V |
| Sampling depth | 10.0 mm |
| Nebulizer gas | 1.07 L/min |
| Makeup gas | − |
| Nebulizer pump | 0.1 rps |
| S/C temperature | 2°C |
| Acquisition mode | Spectrum |
| Peak pattern | 3 points |
| Replicates | 3 |
| Sweeps per replicate | 100 |
| Monitored elements for calculations | 75 As and 72Ge |
| Integration time per mass | 1.0 s for 75 As, 0.3 s for 72Ge |
| Uptake speed | 0.3 rps |
| Uptake time | 40 s |
| Stabilization time | 40 s |
Clinical chemistry parameters.
| Group name | Biochemical parameters | ||||
|---|---|---|---|---|---|
| AST (U/L) | ALT (U/L) | ALP (U/L) | BUN (mmol/L) | CREA ( | |
| Control group | 85.92 ± 7.88 | 30.37 ± 5.58 | 98.12 ± 10.86 | 6.78 ± 0.74 | 45.38 ± 5.35 |
| Group R | 106.12 ± 12.39 | 43.68 ± 4.71 | 116.48 ± 16.17 | 7.47 ± 1.39 | 47.22 ± 7.58 |
| Group NJT | 79.15 ± 6.91 | 28.83 ± 3.30 | 90.43 ± 12.17 | 7.87 ± 1.56 | 48.47 ± 8.02 |
| Group RBC | 111.30 ± 14.14 | 45.52 ± 4.90 | 123.12 ± 15.87 | 8.43 ± 1.23 | 52.32 ± 7.33 |
| Group RBS | 103.42 ± 10.01 | 40.63 ± 6.20 | 116.12 ± 12.37 | 7.77 ± 2.12 | 45.92 ± 13.65 |
| Group RGF | 113.17 ± 13.15 | 48.73 ± 3.46 | 131.07 ± 12.21 | 7.03 ± 1.56 | 50.92 ± 8.65 |
| Group RRR | 90.92 ± 9.79 | 34.66 ± 3.52 | 101.78 ± 13.15 | 6.37 ± 0.95 | 52.12 ± 8.07 |
| Group RSR | 88.52 ± 5.84 | 36.07 ± 4.18 | 105.63 ± 15.89 | 6.18 ± 1.24 | 47.03 ± 8.52 |
| Group RPR | 93.87 ± 6.88 | 33.47 ± 4.06 | 112.63 ± 11.06 | 7.82 ± 1.89 | 43.18 ± 9.32 |
| Group RGR | 97.22 ± 9.00 | 35.52 ± 6.80 | 108.63 ± 14.92 | 8.17 ± 1.65 | 50.10 ± 8.03 |
| Group RFH | 90.80 ± 9.97 | 26.05 ± 7.39 | 99.18 ± 15.37 | 7.88 ± 1.64 | 42.47 ± 7.97 |
Statistics: p < 0.05 versus the control group. Data are presented as mean ± SD of six animals per group.
Figure 1PCA scores plot (a) derived from 1H NMR spectra of the serum from the 11 groups (R2X = 0.834, Q2 = 0.706). PLS-DA scores plot and corresponding loadings plot based on 1H NMR spectra of the serum from the control group and groups R, RBC, RBS, RGF, RRR, RSR, RPR, RGR, and RFR (b, c) (R2X = 0.469, R2Y = 0.688, Q2 = 0.525) and from the control group and groups R, NJT, and RFH (d, e) (R2X = 0.503, R2Y = 0.735, Q2 = 0.604). Key: control group (), group R (), group NJT (), group RBC (), group RBS (), group RGF (), group RRR (), group RSR (), group RPR (), group RGR (), and group RFH ().
Figure 2The summary of pathway analysis in the serum of realgar-exposed mice compared with control mice. Each circle represents one metabolic pathway; the size of circle shows the positive correlation with the impact of each pathway; the colour of circle denotes the significance from the highest value in red to the lowest value in white. (1) Valine, leucine, and isoleucine biosynthesis; (2) synthesis and degradation of ketone bodies; (3) glyoxylate and dicarboxylate metabolism; (4) pyruvate metabolism; (5) citrate cycle; (6) glycolysis or gluconeogenesis; (7) butanoate metabolism.
Results of the pathway analysis.
| Pathway name | Compounds | Hits | Raw | −Log ( | Holm | FDR | Impact |
|---|---|---|---|---|---|---|---|
| Valine, leucine, and isoleucine biosynthesis | 11 | 3 | 0.000076 | 9.4822 | 0.0061718 | 0.0061718 | 0.66666 |
| Butanoate metabolism | 20 | 3 | 0.000504 | 7.593 | 0.040316 | 0.013607 | 0.10145 |
| Citrate cycle (TCA cycle) | 20 | 3 | 0.000504 | 7.593 | 0.040316 | 0.013607 | 0.19339 |
| Pyruvate metabolism | 22 | 3 | 0.000674 | 7.302 | 0.052587 | 0.013652 | 0.24337 |
| Alanine, aspartate, and glutamate metabolism | 24 | 3 | 0.000878 | 7.0384 | 0.067568 | 0.014216 | 0.06329 |
| Glycolysis or gluconeogenesis | 26 | 3 | 0.0011163 | 6.7977 | 0.084841 | 0.01507 | 0.12753 |
| Glycine, serine, and threonine metabolism | 32 | 3 | 0.0020683 | 6.181 | 0.15512 | 0.023934 | 0 |
| Valine, leucine, and isoleucine degradation | 38 | 3 | 0.0034165 | 5.6791 | 0.25282 | 0.034592 | 0 |
| Aminoacyl-tRNA biosynthesis | 67 | 3 | 0.016835 | 4.0843 | 1 | 0.15151 | 0 |
| D-Glutamine and D-glutamate metabolism | 5 | 1 | 0.042129 | 3.167 | 1 | 0.31022 | 0 |
| Synthesis and degradation of ketone bodies | 5 | 1 | 0.042129 | 3.167 | 1 | 0.31022 | 0.6 |
| Selenoamino acid metabolism | 15 | 1 | 0.12155 | 2.1075 | 1 | 0.7472 | 0 |
| Pantothenate and CoA biosynthesis | 15 | 1 | 0.12155 | 2.1075 | 1 | 0.7472 | 0 |
| Glyoxylate and dicarboxylate metabolism | 16 | 1 | 0.12915 | 2.0468 | 1 | 0.7472 | 0.2963 |
| Cysteine and methionine metabolism | 28 | 1 | 0.21577 | 1.5336 | 1 | 1 | 0.02103 |
| Glycerophospholipid metabolism | 30 | 1 | 0.22941 | 1.4722 | 1 | 1 | 0.02315 |
| Tyrosine metabolism | 42 | 1 | 0.3068 | 1.1815 | 1 | 1 | 0 |
| Arginine and proline metabolism | 44 | 1 | 0.31899 | 1.1426 | 1 | 1 | 0.01198 |
Note. Compounds represent the total number of compounds involved in the pathway; Hits represent the actually matched number from the user uploaded data; Raw p is the original p value calculated from the enrichment analysis; Holm p is the p value adjusted using the Holm–Bonferroni method; FDR is the p value adjusted by the false discovery rate; Impact is the pathway impact value calculated from pathway topology analysis [31].
Precision, accuracy, and recovery of total arsenic in mice whole blood.
| Theoretical concentration (ng/mL) | Found (ng/mL) (mean ± SD, | Overall mean (ng/mL) | Intrabatch RSD (%) ( | Interbatch RSD (%) ( | RE (%) ( | Recovery (%) (mean ± SD, | ||
|---|---|---|---|---|---|---|---|---|
| Batch 1 | Batch 2 | Batch 3 | ||||||
| 5 | 4.62 ± 0.46 | 4.66 ± 0.40 | 4.38 ± 0.27 | 4.55 | 9.89 | 8.35 | −9.00 | 93.29 ± 5.46 |
| 10 | 9.41 ± 0.64 | 9.02 ± 0.73 | 9.34 ± 0.52 | 9.26 | 6.80 | 6.62 | −7.40 | 94.56 ± 1.90 |
| 400 | 395.28 ± 22.13 | 375.12 ± 16.94 | 383.92 ± 22.53 | 384.77 | 5.60 | 5.45 | −3.81 | 97.13 ± 2.70 |
| 600 | 575.20 ± 23.99 | 597.44 ± 13.99 | 603.68 ± 21.05 | 592.11 | 4.17 | 3.80 | −1.32 | 98.34 ± 2.05 |
Figure 3Arsenic accumulation in whole blood of mice. (A) Group R (B) Group NJT. (C) Group RBC. (D) Group RBS. (E) Group RGF. (F) Group RRR. (G) Group RSR. (H) Group RPR. (I) Group RGR. (J) Group RFH. p < 0.05 versus group R (n = 6).